Eszter Varga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eszter Varga has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Emile van Den Akker
Department of Hematopoiesis and Sanquin Research, Landsteiner Laboratory, Department of Molecular Hematology, Amsterdam UMC, University of Amsterdam, The Netherlands
3 shared publications Marieke von Lindern
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
3 shared publicationsChantal C. Clark
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publicationsElise J. Huisman
Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center, Rotterdam, the Netherlands
2 shared publicationsEmile van Den Akker
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publicationsHuan Zhang
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Elsevier in Stem Cell Research
- Vol. 97
Generation of CD43-P2A-mNeonGreen reporter human pluripotent stem cell line using CRISPR Cas9
- 1 November 2026
- Published by Elsevier in Stem Cell Research
- Vol. 97
Open AccessGeneration of CD43-P2A-mNeonGreen reporter human pluripotent stem cell line using CRISPR Cas9
- Open Access
- 15 July 2025
- Published by Elsevier in Stem Cell Research
- Vol. 87, 103771
Generation and characterization of human iPSC line SANi011-A from a patient with an inherited platelet disorder carrying the heterozygous FLI1 c.297del variant
- 15 July 2025
- Published by Elsevier in Stem Cell Research
- Vol. 87, 103771
Open AccessGeneration and characterization of human iPSC line SANi011-A from a patient with an inherited platelet disorder carrying the heterozygous FLI1 c.297del variant
- Open Access
- 12 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (38) , e04725
Large‐Scale Production of Transfusion‐Ready Red Blood Cells From Induced Pluripotent Stem Cells
There is a constant worldwide need for blood products, traditionally obtained from donations. In vitro red blood cell (RBC) production could supplement this demand and offer benefits such as thorough screening for improved safety, the possibility of genetic manipulation to restore genetic deficiencies, and therapeutic loading. Induced pluripotent stem cells (iPSCs) are a promising cell source for transfusable RBCs due to their immortality and independence from donors. However, current iPSC differentiation protocols—including both monolayer and embryoid body‐based systems—have failed to produce sufficient erythroid cells (10 11–12 per unit) for therapeutic application, primarily due to developmental immaturity, inefficient enucleation (5–25%), and suboptimal, static culture conditions lacking physiological relevance. This study describes the optimization of an iPSC to RBC differentiation platform and its step‐by‐step translation process to dynamic culture conditions, allowing scalability and eventual bioreactor application. The optimized dynamic culture yields ≈4.6 × 10 3 RBC/iPSC, requiring an estimated ≈4.9 × 10 7 iPSCs to produce a minitransfusion unit, achieving a consistent 40–70% enucleation rate and bona fide function, demonstrated by both in vitro and in vivo assays. Our feeder‐free, GMP‐compatible system accomplishes an enucleated RBC production rate sufficient for large‐scale application and serves as a bridge to large‐scale bioreactor RBC production, facilitating clinical application.
- 12 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (38) , e04725
Open AccessLarge‐Scale Production of Transfusion‐Ready Red Blood Cells From Induced Pluripotent Stem Cells
There is a constant worldwide need for blood products, traditionally obtained from donations. In vitro red blood cell (RBC) production could supplement this demand and offer benefits such as thorough screening for improved safety, the possibility of genetic manipulation to restore genetic deficiencies, and therapeutic loading. Induced pluripotent stem cells (iPSCs) are a promising cell source for transfusable RBCs due to their immortality and independence from donors. However, current iPSC differentiation protocols—including both monolayer and embryoid body‐based systems—have failed to produce sufficient erythroid cells (10 11–12 per unit) for therapeutic application, primarily due to developmental immaturity, inefficient enucleation (5–25%), and suboptimal, static culture conditions lacking physiological relevance. This study describes the optimization of an iPSC to RBC differentiation platform and its step‐by‐step translation process to dynamic culture conditions, allowing scalability and eventual bioreactor application. The optimized dynamic culture yields ≈4.6 × 10 3 RBC/iPSC, requiring an estimated ≈4.9 × 10 7 iPSCs to produce a minitransfusion unit, achieving a consistent 40–70% enucleation rate and bona fide function, demonstrated by both in vitro and in vivo assays. Our feeder‐free, GMP‐compatible system accomplishes an enucleated RBC production rate sufficient for large‐scale application and serves as a bridge to large‐scale bioreactor RBC production, facilitating clinical application.
- Open Access
- 5 July 2025
- Published by Elsevier in Stem Cell Research
- Vol. 87, 103769
Generation and characterization of human iPSC line SANi012-A from a patient with an inherited platelet disorder carrying the heterozygous ETV6 c.1105C > T variant
- 5 July 2025
- Published by Elsevier in Stem Cell Research
- Vol. 87, 103769
Open AccessGeneration and characterization of human iPSC line SANi012-A from a patient with an inherited platelet disorder carrying the heterozygous ETV6 c.1105C > T variant
- Open Access
Efficient production of erythroid, megakaryoid and myeloid cells, using single cell-derived iPSC colony differentiation
Hematopoietic differentiation of human induced pluripotent stem cells (iPSCs) provide opportunities not only for fundamental research and disease modelling/drug testing but also for large-scale production of blood effector cells for future clinical application. Although there are multiple ways to differentiate human iPSCs towards hematopoietic lineages, there is a need to develop reproducible and robust protocols. Here we introduce an efficient way to produce three major blood cell types using a standardized differentiation protocol that starts with a single hematopoietic initiation step. This system is feeder-free, avoids EB-formation, starts with a hematopoietic initiation step based on a novel single cell-derived iPSC colony differentiation and produces multi-potential progenitors within 8-10 days. Followed by lineage-specific growth factor supplementation these cells can be matured into well characterized erythroid, megakaryoid and myeloid cells with high-purity, without transcription factor overexpression or any kind of pre-purification step. This standardized differentiation system provides a simple platform to produce specific blood cells in a reproducible manner for hematopoietic development studies, disease modelling, drug testing and the potential for future therapeutic applications. Highlights: Efficient hematopoietic differentiation from single cell-derived iPSC colonies Reproducible feeder-free, monolayer differentiation system independent of iPSC line Production of erythroid, megakaryoid and myeloid cells with high-purity Platform for hematopoietic developmental research and future clinical application
Open AccessEfficient production of erythroid, megakaryoid and myeloid cells, using single cell-derived iPSC colony differentiation
Hematopoietic differentiation of human induced pluripotent stem cells (iPSCs) provide opportunities not only for fundamental research and disease modelling/drug testing but also for large-scale production of blood effector cells for future clinical application. Although there are multiple ways to differentiate human iPSCs towards hematopoietic lineages, there is a need to develop reproducible and robust protocols. Here we introduce an efficient way to produce three major blood cell types using a standardized differentiation protocol that starts with a single hematopoietic initiation step. This system is feeder-free, avoids EB-formation, starts with a hematopoietic initiation step based on a novel single cell-derived iPSC colony differentiation and produces multi-potential progenitors within 8-10 days. Followed by lineage-specific growth factor supplementation these cells can be matured into well characterized erythroid, megakaryoid and myeloid cells with high-purity, without transcription factor overexpression or any kind of pre-purification step. This standardized differentiation system provides a simple platform to produce specific blood cells in a reproducible manner for hematopoietic development studies, disease modelling, drug testing and the potential for future therapeutic applications. Highlights: Efficient hematopoietic differentiation from single cell-derived iPSC colonies Reproducible feeder-free, monolayer differentiation system independent of iPSC line Production of erythroid, megakaryoid and myeloid cells with high-purity Platform for hematopoietic developmental research and future clinical application
- Open Access
- 1 December 2017
- Published by Elsevier in Stem Cell Research
- Vol. 25, 34-37
Generation and characterization of a human iPSC line SANi005-A containing the gray platelet associated heterozygous mutation p.Q287* in GFI1B
- 1 December 2017
- Published by Elsevier in Stem Cell Research
- Vol. 25, 34-37
Open AccessGeneration and characterization of a human iPSC line SANi005-A containing the gray platelet associated heterozygous mutation p.Q287* in GFI1B